Blood flow between heart chambers is regulated by native valves—the mitral valve, the aortic valve, the pulmonary valve, and the tricuspid valve. Each of these valves is a passive one-way valve that opens and closes in response to differential pressures. Patients with valvular disease have abnormal anatomy and/or function of at least one valve. For example, a valve may suffer from insufficiency, also referred to as regurgitation, when the valve does not fully close, thereby allowing blood to flow retrograde. Valve stenosis can cause a valve to fail to open properly. Other diseases may also lead to dysfunction of the valves.
The mitral valve, for example, sits between the left atrium and the left ventricle and, when functioning properly, allows blood to flow from the left atrium to the left ventricle while preventing backflow or regurgitation in the reverse direction. Native valve leaflets of a diseased mitral valve, however, do not fully prolapse, causing the patient to experience regurgitation.
While medications may be used to treat diseased native valves, the defective valve often needs to be repaired or replaced at some point during the patient's lifetime. Existing prosthetic valves and surgical repair and/or replacement procedures may have increased risks, limited lifespans, and/or are highly invasive. Some less invasive transcatheter options are available, but most are not ideal. A major limitation of existing transcatheter mitral valve devices, for example, is that the mitral valve devices are too large in diameter to be delivered transeptally, requiring transapical access instead. Furthermore, existing mitral valve replacement devices are not optimized with respect to strength-weight ratio and often take up too much space within the valve chambers, resulting in obstruction of outflow from the ventricle into the aorta and/or thrombosis.
Thus, a new valve device that overcomes some or all of these deficiencies is desired.
A device for treating a diseased native valve in a patient is provided, the device comprising a frame structure; a valve segment positioned radially within the frame structure, the valve segment comprising a plurality of leaflets, and a plurality of commissure attachment mechanisms coupling the leaflets to the frame structure, each commissure attachment mechanism extending radially inwards from an outflow end of the frame structure as to create a gap between an interior diameter of the outflow end and an outflow edge of the valve segment.
In some embodiments, an inflow edge of the valve segment is unsupported by the frame structure. In other embodiments, the inflow edge is spaced radially inwards from an inflow end of the frame structure. In some embodiments, an inflow end of the frame structure is flared radially outwards.
In one embodiment, the outflow end of the frame structure is flared radially outwards, and wherein tips of the outflow end point substantially axially.
In some embodiments, the commissure attachment mechanisms each comprise a paddle, the paddle including a slot therein through which tabs of the leaflet commissures pass.
In one example, the paddle further comprises a plurality of holes therethrough for sewing attachment of the tabs to the paddle.
In another embodiment, the commissure attachment mechanisms each include a post that attaches to the outflow end of the frame structure and curves radially inwards.
In some examples the post curves in approximately 180 degrees.
In some embodiments, the post attaches to a strut of the outflow end, and wherein a thickness of the post is greater than a thickness of the strut.
In one embodiment, the gap is between 1.5 mm and 4 mm when the leaflets are fully opened.
In some examples, the leaflets are unsupported except at the commissure attachment mechanisms.
In some embodiments, the device further comprises a spiral anchor configured to be placed around the frame structure.
In some embodiments, the frame structure comprises a plurality of struts, and wherein the struts have a narrowed portion proximate to the spiral anchor.
A device for treating a diseased native valve in a patient is also provided, the device comprising a frame structure comprising a central annular portion, an inflow portion, and an outflow portion, wherein the outflow portion is flared radially outwards relative to the central annular portion; a valve segment positioned radially within the frame structure, the valve segment comprising a plurality of leaflets, and a plurality of commissure attachment mechanisms coupling the leaflets to the outflow portion of the frame structure, each commissure attachment mechanism extending radially inwards such that an inner circumference formed by the commissure attachment mechanisms is approximately equal to an inner circumference of the central annular portion.
In some embodiments, an inflow edge of the valve segment is unsupported by the frame structure. In other embodiments, the inflow edge is spaced radially inwards from the inflow portion of the frame structure. In some examples, the inflow portion of the frame structure is flared radially outwards.
In some embodiments, tips of the outflow portion point substantially axially. In one embodiment, the commissure attachment mechanisms each comprise a paddle, the paddle including a slot therein through which tabs of the leaflet commissures pass.
In another embodiment, the paddle further comprises a plurality of holes therethrough for sewing attachment of the tabs to the paddle.
In some examples, the commissure attachment mechanisms each include a post that attaches to the outflow portion of the frame structure and curves radially inwards.
In one embodiment, the post curves in approximately 180 degrees. In other examples, the post attaches to a strut of the outflow portion, and wherein a thickness of the post is greater than a thickness of the strut.
In one embodiment, a gap between an outflow edge of the valve segment and an inner perimeter (e.g., diameter) of the outflow portion of the frame structure is between 1.5 mm and 4 mm when the leaflets are fully opened.
In some examples, the leaflets are unsupported except at the commissure attachment mechanisms.
In one embodiment, the device further comprises a spiral anchor configured to be placed around the frame structure at the central annular portion.
In some examples, the frame structure comprises a plurality of struts, and wherein the struts have a narrowed portion within the central annular portion.
A device for treating a diseased native valve in a patient is provided, the device comprising a frame structure comprising an annular central portion, a flared inflow portion, and a flared outflow portion, a valve segment positioned radially within the frame structure, the valve segment comprising a plurality of leaflets, and an internal skirt attached to the frame structure, the internal skirt comprising a plurality of convex segments configured to at least partially conform to inflow edges of the leaflets.
In some embodiments, the convex segments have a greater radius of curvature than the inflow edges of the leaflets.
In one example, an outflow edge of the internal skirt comprises a zig-zag pattern configured to match a cell pattern of the frame structure. In other examples, an outflow edge of the internal skirt is attached to the frame proximate to the annular central portion. In another embodiment, an outflow edge of the internal skirt does not extend to an outflow end of the frame structure.
In some examples, the inflow edges of the leaflets are unsupported by the frame structure. In another embodiment, the inflow edges of the leaflets are spaced radially inwards from an inflow end of the frame structure.
In some embodiments, the device further comprises a spiral anchor configured to be placed around the frame structure.
A device for treating a diseased native valve in a patient is provided, the device comprising a frame structure comprising an annular central portion, a flared inflow portion, and a flared outflow portion; a valve segment positioned radially within the frame structure, the valve segment comprising a plurality of leaflets, and an external skirt attached to the frame structure, the external skirt comprising a unitary structure covering the flared inflow portion and the flared outflow portion.
In some examples, the external skirt comprises a tube knit fabric. In another embodiment, the external skirt comprises a coating thereon.
In some embodiments, the device further comprises a spiral anchor configured to be placed around the frame structure.
In one embodiment, the external skirt is wrapped over an outflow edge of the frame structure.
In another embodiment, an additional skirt layered with the external skirt. In some examples, the additional skirt is positioned along the flared outflow portion. In one embodiment, the additional skirt is positioned along a central annular portion of the frame structure.
A device for treating a diseased native valve in a patient is provided, the device comprising a frame structure comprising a flared inflow portion comprising first and second rows of cells; an annular central portion comprising a third row of cells, and a flared outflow portion comprising a fourth row of cells, and a valve segment positioned radially within the frame structure, the valve segment comprising a plurality of leaflets.
In some embodiments, the inflow portion is flared further radially outwards than the outflow portion.
In other embodiments, the inflow portion is curved so as to point radially inwards.
In one embodiment, the device further comprises a plurality of non-foreshortening elements extending from the inflow portion.
In some examples, tips of the outflow portion point substantially axially.
In one embodiment, the third row of cells comprises a plurality of narrowed axially extending struts therein.
In other embodiments, tips of the flared outflow portion point substantially axially.
In some examples, the cells are substantially diamond-shaped.
In another embodiment, the device comprises a spiral anchor configured to be placed around the frame structure at the central annular portion.
In another example, the device includes a plurality of commissure attachment mechanisms coupling the leaflets to the frame structure, each commissure attachment mechanism extending radially inwards from an outflow end of the frame structure as to create a gap between an interior diameter of the outflow end and an outflow edge of the valve segment.
A method for treating a diseased native valve in a patient is provided, comprising: providing a device including a frame structure, a valve segment positioned radially within the frame structure, the valve segment comprising a plurality of leaflets, and a plurality of commissure attachment mechanisms coupling the leaflets to the frame structure; advancing the device to the diseased native valve in the patient; deploying the device within the diseased native valve to secure the device to the diseased native valve; and allowing an outflow edge of the plurality of leaflets to open to a radius that is greater than a radius formed by the plurality of commissure attachment mechanisms.
In some embodiments, the outflow edge of the plurality of leaflets is allowed to open to a radius that is less than an inner perimeter of the frame structure.
In other embodiments, the opening of the plurality of leaflets is configured to maintain a cylindrical flow path.
A method for treating a diseased native valve in a patient is provided, comprising: providing a device including a frame structure, a valve segment positioned radially within the frame structure, the valve segment comprising a plurality of leaflets, and a plurality of commissure attachment mechanisms coupling the leaflets to the frame structure, wherein the plurality of commissure attachment mechanisms extend radially inwards such that an inner circumference formed by the commissure attachment mechanisms is less than an inner circumference formed by the frame structure; advancing the device to the diseased native valve in the patient; deploying the device within the diseased native valve to secure the device to the diseased native valve; and allowing an outflow edge of the plurality of leaflets to open to a radius that is greater than a radius formed by the plurality of commissure attachment mechanisms.
In some embodiments, the outflow edge of the plurality of leaflets is allowed to open to a radius that is less than an inner perimeter of the frame structure.
In other embodiments, the opening of the plurality of leaflets is configured to maintain a cylindrical flow path.
The novel features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the present disclosure are utilized, and the accompanying drawings of which:
Described herein are systems, devices, and methods for treatment or replacement of a diseased native valve of the heart, such as the mitral valve.
In general, described herein is a replacement prosthesis that can include a valve frame and a spiral anchor therearound.
The valve prosthesis 10 can be deployed in an expanded configuration according to the methods described herein. For example, valve prosthesis 10 can be deployed into an expanded configuration in a method of replacing or repairing a native anatomical structure. In the expanded configuration, valve prosthesis 10 can be positioned and/or anchored at a target region of a subject (e.g., an organ or tissue of an animal such as a dog, cat, horse, or human). For example, valve prosthesis 10 can be positioned in the expanded configuration in the orifice of a heart valve, such as the mitral valve or tricuspid valve (e.g., to function as a temporary or permanent replacement for an existing mitral valve or tricuspid valve of the heart).
One or more portions of the valve frame 12a can be shaped or configured to aid in securing the valve frame 12 at a location (e.g., in the orifice of a native heart valve). For example, the valve frame 12a can include an atrial flared portion 102 and a ventricular flared portion 103 configured to help secure the frame in the anatomy. The atrial and ventricular flared portions 102, 103 can extend radially outwards from a central annular portion 101. The atrial flared portion 102 can, for example, extend into the atrium of the heart from the central annular portion 101 when the valve prosthesis is deployed in the native mitral valve. The ventricular flared portion 103, in turn, can extend into the ventricle of the heart from the central annular portion 101 when the valve prosthesis is deployed in the native mitral valve. The atrial and ventricular flared portions 102, 103 can, for example, be configured to be positioned on either side of an external flat spiral anchor (e.g., that is wrapped around the chordae) to anchor the valve frame 12 in the anatomy. Alternatively or additionally, the atrial and ventricular flared portions 102, 103 can be configured to engage with tissue to prevent the valve prosthesis from slipping through the native valve orifice.
Referring to
As shown in
Further, as shown in
In some embodiments, the longitudinal length 127 of the collapsed valve frame 12a can be minimized, which can be advantageous for delivery of the valve frame 12a. For example, minimizing the overall longitudinal length of the collapsed valve frame 12a can allow improved maneuverability within a delivery device while maintaining structural strength of the device. In some embodiments, minimizing the overall longitudinal length of the collapsed valve frame 12a can allow insertion of valve frame 12a through an access path that would be challenging for a longer device to traverse (e.g., an access path comprising tortuous passages or passages with sharp turns). In some embodiments, the valve frame 12a in the unexpanded configuration can have an overall longitudinal length of from 1 mm to 50 mm, from 1 mm to 45 mm, from 1 mm to 40 mm, from 1 mm to 35 mm, from 1 mm to 30 mm, from 1 mm to 25 mm, from 1 mm to 20 mm, from 1 mm to 10 mm, from 10 mm to 45 mm, from 20 mm to 45 mm, from 20 mm to 30 mm, from 25 mm to 35 mm, or from 27.5 mm to 32.5 mm. In some embodiments, the valve frame 12a in the expanded configuration can have an overall longitudinal length of from 1 mm to 45 mm, from 10 mm to 45 mm, from 15 mm to 45 mm, from 15 mm to 35 mm, from 16 mm to 34 mm, from 17 mm to 33 mm, from 18 mm to 32 mm, from 19 mm to 31 mm, from 20 mm to 30 mm, from 25 mm to 35 mm, or from 27.5 mm to 32.5 mm. In some embodiments, the valve frame 12a can foreshorten as it expands such that the length in the expanded configuration is less than the length in the collapsed configuration.
In some embodiments, the valve frame 12a and/or overall prosthesis can have specific features designed to increase stiffness, improve control over valve deployment, promote uniform radial expansion of the central annular portion, ensure anchoring within the annulus, and/or decrease PVL.
Further, the diameter 128 of the collapsed valve prosthesis 10 can be minimized, which can likewise be advantageous for delivery of the valve prosthesis 10. For example, a collapsed valve prosthesis 10 with a smaller diameter 128 can fit inside of a delivery device with a smaller diameter, allowing for less invasive delivery and for improved maneuvering capability inside of a subject's body. Reducing the diameter 128 of the collapsed valve prosthesis 10 (e.g., for use in treatment or replacement of a mitral valve, a tricuspid valve, an aortic valve, or a pulmonic valve) can further allow for easier delivery of the valve prosthesis 10 to a target region of a subject, faster recovery of a subject receiving valve prosthesis 10, and/or improved clinical outcomes for a subject receiving valve prosthesis 10 (e.g., improved subject survival, improved ejection fraction, improved cardiac output, decreased valvular regurgitation, and/or decreased edema). In some cases, reducing the diameter 128 of the collapsed valve prosthesis 10 can make transseptal access and delivery possible in addition to transapical access. In some cases, the diameter 128 of the collapsed valve prosthesis 10 or portion thereof (e.g., frame structure 12) can be from 0.01 mm to 20 mm, 0.01 mm to 15 mm, 0.01 mm to 10 mm, from 0.01 mm to 9 mm, from 0.01 mm to 8 mm, from 0.01 mm to 7 mm, from 0.01 mm to 6 mm, from 0.01 mm to 5 mm, from 0.01 mm to 4 mm, from 0.01 mm to 3 mm, from 0.01 mm to 2 mm, from 0.01 mm to 1 mm, from 1 mm to 15 mm, from 2 mm to 14 mm, from 3 mm to 13 mm, from 4 mm to 12 mm, from 5 mm to 10 mm, from 6 mm to 10 mm, from 7 mm to 10 mm, from 8 mm to 10 mm, from 9 mm to 10 mm, from 10 mm to 15 mm, no more than 20 mm, no more than 15 mm, no more than 10 mm, no more than 9 mm, no more than 8 mm, no more than 7 mm, no more than 6 mm, or no more than 5 mm.
In some cases, the valve prosthesis 10 or a portion thereof can be sized or shaped to be positioned at a certain location or target region. For example, the frame structure 12 can be sized to be positioned in a valve, such as the mitral valve (e.g., by designing a dimension of frame structure to fit a valve, such as the mitral valve, when in an expanded configuration).
In some embodiments, the valve prostheses 10 described herein can include one or more flared portions to engage with the anchor 15 and/or help prevent the valve prostheses 10 from sliding through a valve orifice. For example, as shown in
Referring to
Any of the valve segments 14 described herein may be formed of multi-layered materials for preferential function. Referring to
The valve segment 14 may be attached to a frame structure 12, which can in turn be attached to the anchor 15. The frame structure 12 may be connected to the anchor 15 before or after the frame structure 12 has been deployed adjacent a native valve. The frame structure 12 may be attached to the valve segment 12, for example, via attachment of the frame structure 12 to the seal 177, which can in turn be attached to the leaflets 16.
In some embodiments, two or more portions of a valve segment 14 (e.g., two or more leaflets 16, and/or seal 177) can comprise a single piece of material (e.g., a single piece of biological or synthetic tissue formed into the shape of a functional valve). In some cases, two or more portions of a valve segment (e.g., two or more of a first and second leaflet 16, and/or the seal 177) can be joined together. In some embodiments, two or more portions of a valve segment (e.g., two or more of a first and second leaflet 16, and/or the seal 177) can be joined together by suturing the two or more portions together (e.g., at convex segment 166 shown in
In many cases, convex segment 166 is disposed at an inflow end of valve prosthesis 10 (i.e., closest to the source of flow through the device, e.g., caused by a contracting heart chamber) when deployed. In some cases, coupling two or more portions of a valve segment 14 at the inflow end of valve prosthesis 10 (or portion thereof) allows the valve segment 14 to fold or collapse (e.g., radially away from a longitudinal axis of valve prosthesis device 10) during contraction of a heart chamber upstream of the deployed device (i.e., during diastole). Further, in some cases, coupling two or more portions of a valve segment 14 at the inflow end of valve prosthesis 10 causes the valve segment 14 to expand (e.g., radially toward a longitudinal axis of valve prosthesis device 10) during refilling of a heart chamber upstream of the deployed device (i.e., during systole). This expansion of the valve segment 14 can, for example, result in billowing or parachuting of the valve segment 14 (e.g., between the seal 177 and the leaflets 16) to block the flow of blood therethrough.
As shown in
In some embodiments, a portion of a valve segment 14 (e.g., leaflets 16 or seal 177) can be sutured to one or more outflow portion of frame structure 12 and not to the inflow portion of frame structure 12 (e.g., can be sutured to one or more distal arches 116 but not one or more proximal arches 115 as shown in
In some embodiments, a portion of the valve segment 14 can be sutured or otherwise attached with an outflow attachment mechanism (e.g., with inwardly extending commissure attachment mechanisms as illustrated and described further herein) and not to the inflow portion of the frame. In some embodiments, a portion of a valve segment 14 (e.g., leaflets 16 or seal 177) can be sutured to one or more outflow portion of frame structure 12 and to the inflow portion of frame structure 12 (e.g., can be sutured to one or more distal arches 116 and also to one or more proximal arches 115 as shown in valve prosthesis 10E of
In some cases, the amount of attachment of a valve segment 14 (e.g., a valve leaflet 16) to the frame structure 12 can be minimized, which can advantageously enhance ease of delivery and reduce the required length of the frame, thereby reducing the chance of thrombosis and reducing the chance of blocking the outflow from the ventricle to the aorta. Minimizing the frame structure 12 can also improve the speed and cost of fabrication of the valve prosthesis device 10.
In some embodiments, a leaflet 16 that is attached to a first portion of frame structure 12 (e.g., one or more struts 113) at a distal end of frame structure 12 can be unattached at a proximal end of the frame structure 12 (e.g., a strut or portion thereof at a proximal end of frame structure 12). In some cases, valve prosthesis devices 10 in which a valve segment 14 is attached at a proximal end of frame structure 12 and is unattached at a proximal end of frame structure 12 (and/or at a proximal end of valve segment 14) may require less metal and/or fewer struts than a valve prosthesis 10 in which a valve segment 14 is attached at both a proximal end and a distal end of the frame structure 12 of the valve prosthesis device 10. In some cases, minimizing the amount of metal used in the structure of valve prosthesis 10 (e.g., by reducing the number and/or length of struts in valve prosthesis device 10) can reduce the risk of thrombus formation and can improve the ease with which the device is deployed at a target location.
Further, the valve segment 14 can be configured to be substantially unsupported at the inflow edge 95 of the valve segment 14. For example, as shown in
Referring to
As shown in
In some embodiments, the commissure attachment mechanisms 1111 can have a width or thickness that is greater than the width or thickness of the cell strut or distal arch 116 or other cells 122 of the frame structure 12a. In some embodiments, this increased width or thickness of the commissure attachment mechanism 1111 can help ensure that the attachment mechanism 1111 stays substantially rigid and/or unbending even during opening and closing of the leaflets 16. In other embodiments, the increased width or thickness of the attachment mechanism 1111 can be configured to enable slight bending, thereby distributing strain between the commissure attachment mechanism 1111 and the frame 12a.
As shown in
As a result of the interior commissure attachment mechanism 1111, the attached edges of the leaflets 16 can extend substantially straight down from the central annular portion 101 (i.e., without curving radially outwards). The free (e.g., outflow) edge of the leaflet (e.g., between commissure attachment mechanisms 1111) can open to a radius that is greater than id, without contacting frame 12a. That is, as shown in
In some embodiments described herein, the inflow edge 95 of the leaflets can be entirely unsupported except at commissures of the leaflets 16, such as except for at the interior commissure attachment mechanism 1111 and/or the minimal valve supports 124.
Another exemplary frame 12e is shown in
Another exemplary frame 12f is shown in
Another exemplary frame 12g is shown in
A table showing exemplary dimensions for frames 12a, 12e, 12f, and 12g is shown in
Another exemplary frame 12h is shown in
Referring to
Any of the valve frames 12 (e.g., frame 12a-12h) described herein can include one or more skirts or seals thereon. For example, the valve frame 12 can include an internal skirt and one or more external skirts. The skirts can be made, for example, of PET.
Referring to
Referring to
Referring to
Referring to
Referring to
The skirts described herein can be made of a polymer, such as polyethylene terephthalate (PET). Further, the skirts described herein can be woven and/or knitted (e.g., with a denier of 15-25, such as approximately 20). For example,
Any of the skirts described herein can include a coating, such as a chronoflex AR coating, to reduce the pore size of the skirt and increase resistance to fluid flow therethrough. For example, in some embodiments, only the external atrial skirt 224 can include a coating thereon. In other embodiments, both the external and atrial skirts 224, 225 (either individual or unitary) can include a coating thereon.
As described herein, the valve prosthesis may include a frame structure (e.g., with a tapered waist and atrial and ventricular flared portions) with leaflets therein. In some embodiments, the leaflets can be formed of multi-layered materials for preferential function. The leaflets may be attached directly to the frame structure. Alternatively, the leaflets may be attached to an intermediate valve structure that is in turn connected to the frame structure. The leaflets may be connected to the frame structure before or after the frame structure has been deployed adjacent a native valve. The leaflets may comprise a biocompatible one-way valve. Flow in one direction may cause the leaflets to deflect open and flow in the opposite direction may cause the leaflets to close. The frame structure may be configured like a stent. The frame structure may, for example, comprise a scaffold in a diamond pattern formed from a shape memory material (e.g., nitinol, NiTi). One of ordinary skill in the art will appreciate that many other structures, materials, and configurations may be employed for the frame structure. For example, the frame structure may be formed of a polymer of sufficient elasticity. The frame structure may be formed of a combination of metal and polymer, such as metal (e.g., shape memory material) covered in polymer. The frame structure may include a variety of patterns besides diamond shapes. In some embodiments, the frame structure is a closed frame such that blood flow is forced through the leaflets therein. One or more skirts and/or seals may help force blood through the leaflets. Exemplary frame structures and valve prostheses are described in PCT Application No. PCT/US2019/047542, filed Aug. 21, 2019, titled “PROSTHETIC CARDIAC VALVE DEVICE, SYSTEMS, AND METHODS,” now PCT Publication No. WO 2020/041495 in International Patent Application No. PCT/US2020/027744, filed Apr. 10, 2020, titled “MINIMAL FRAME PROSTHETIC CARDIAC VALVE DELIVERY DEVICES, SYSTEMS, AND METHODS,” now PCT Publication No. WO 2020/210685, and in International Patent Application No. PCT/US2021/037661, filed Jun. 16, 2021, titled “MINIMAL FRAME PROSTHETIC CARDIAC VALVE DELIVERY DEVICES, SYSTEMS, AND METHODS,” the entireties of which are incorporated by reference herein.
Additionally, in some embodiments, the valve prostheses described herein include one or more anchors. The anchor may include a flat spiral shape with a plurality of windings or loops spiraling radially outwards from a central point. The loops of the flat spiral shaped anchor may be generally positioned within the same plane. The anchor may be formed from a shape memory material (e.g., NiTi). The anchor can be configured to extend around the chordae of the valve (e.g., the mitral valve) and around the valve prosthesis to hold the valve prosthesis in place. Flat spiral anchors are described in U.S. patent application Ser. No. 16/723,537, filed Dec. 20, 2019, titled “PROSTHETIC CARDIAC VALVE DEVICES, SYSTEMS, AND METHODS,” now U.S. Publication No. US-2020-0261220-A1, the entirety of which is incorporated by reference herein.
The valve prostheses and/or anchors described herein may be delivered via a delivery system. Exemplary delivery systems are described in International Application No. PCT/US2020/023671, filed Mar. 19, 2020, titled “PROSTHETIC CARDIAC VALVE DEVICES, SYSTEMS, AND METHODS,” now PCT Publication No. WO 2020/191216, and in International Application No. PCT/US2021/040623, filed Jul. 7, 2021, titled “VALVE DELIVERY SYSTEM,” the entireties of which are incorporated by reference herein.
It should be understood that any feature described herein with respect to one embodiment can be substituted for or combined with any feature described with respect to another embodiment. For example, it should be understood that any of the frame structures, features of the frame structures (e.g., commissure attachment mechanisms), or skirts described with respect to one embodiment can be interchanged and/or combined with any of the other frame structures described herein.
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.
As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
This application claims the benefit of U.S. Provisional Appln. No. 63/121,812, filed Dec. 4, 2020, titled “MINIMAL FRAME PROSTHETIC CARDIAC VALVE DELIVERY DEVICES, SYSTEMS, AND METHODS,” and to U.S. Provisional Appln. No. 63/173,281, filed Apr. 9, 2021, titled “FLARED PROSTHETIC CARDIAC VALVE DELIVERY DEVICES AND SYSTEMS,” and to U.S. Provisional Appln. No. 63/274,821, filed Nov. 2, 2021, titled “FLARED PROSTHETIC CARDIAC VALVE DELIVERY DEVICES AND SYSTEMS”, all of which are incorporated by reference as if fully set forth herein.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4725274 | Lane et al. | Feb 1988 | A |
| 5002563 | Pyka et al. | Mar 1991 | A |
| 5327905 | Avitall | Jul 1994 | A |
| 5356424 | Buzerak et al. | Oct 1994 | A |
| 5370685 | Stevens | Dec 1994 | A |
| 5582616 | Bolduc et al. | Dec 1996 | A |
| 5716397 | Myers | Feb 1998 | A |
| 5755601 | Jones | May 1998 | A |
| 5779669 | Haissaguerre et al. | Jul 1998 | A |
| 5873835 | Hastings et al. | Feb 1999 | A |
| 5944690 | Falwell et al. | Aug 1999 | A |
| 5997526 | Giba et al. | Dec 1999 | A |
| 6048339 | Zirps et al. | Apr 2000 | A |
| 6053873 | Govari et al. | Apr 2000 | A |
| 6254550 | McNamara et al. | Jul 2001 | B1 |
| 6419695 | Gabbay | Jul 2002 | B1 |
| 6419696 | Ortiz et al. | Jul 2002 | B1 |
| 6530952 | Vesely | Mar 2003 | B2 |
| 6533783 | Töllner | Mar 2003 | B1 |
| 6641553 | Chee et al. | Nov 2003 | B1 |
| 6752813 | Goldfarb et al. | Jun 2004 | B2 |
| 6908478 | Alferess et al. | Jun 2005 | B2 |
| 6964684 | Ortiz et al. | Nov 2005 | B2 |
| 6974476 | McGuckin, Jr. et al. | Dec 2005 | B2 |
| 7077861 | Spence | Jul 2006 | B2 |
| 7101395 | Tremulis et al. | Sep 2006 | B2 |
| 7125421 | Tremulis et al. | Oct 2006 | B2 |
| 7160322 | Gabbay | Jan 2007 | B2 |
| 7175656 | Khairkhahan | Feb 2007 | B2 |
| 7201771 | Lane | Apr 2007 | B2 |
| 7226467 | Lucatero et al. | Jun 2007 | B2 |
| 7381219 | Salahieh et al. | Jan 2008 | B2 |
| 7329279 | Haug et al. | Feb 2008 | B2 |
| 7445631 | Salahieh et al. | Nov 2008 | B2 |
| 7470285 | Nugent et al. | Dec 2008 | B2 |
| 7527647 | Spence | May 2009 | B2 |
| 7534261 | Freidman | May 2009 | B2 |
| 7563267 | Goldfarb et al. | Jul 2009 | B2 |
| 7594903 | Webler et al. | Sep 2009 | B2 |
| 7604646 | Goldfarb et al. | Oct 2009 | B2 |
| 7608091 | Goldfarb et al. | Oct 2009 | B2 |
| 7618449 | Tremulis et al. | Nov 2009 | B2 |
| 7621948 | Herrmann et al. | Nov 2009 | B2 |
| 7666204 | Thornton et al. | Feb 2010 | B2 |
| 7704269 | St. Goar et al. | Apr 2010 | B2 |
| 7731705 | Wardle | Jun 2010 | B2 |
| 7748389 | Salahieh et al. | Jul 2010 | B2 |
| 7749266 | Forster et al. | Jul 2010 | B2 |
| 7780725 | Haug et al. | Aug 2010 | B2 |
| 7799069 | Bailey et al. | Sep 2010 | B2 |
| 7811296 | Goldfarb et al. | Oct 2010 | B2 |
| 7824442 | Salahieh et al. | Nov 2010 | B2 |
| 7824443 | Salahieh et al. | Nov 2010 | B2 |
| 7846203 | Cribier | Dec 2010 | B2 |
| 7942927 | Kaye et al. | May 2011 | B2 |
| 7947075 | Goetz et al. | May 2011 | B2 |
| 7951195 | Antonsson et al. | May 2011 | B2 |
| 7959666 | Salahieh et al. | Jun 2011 | B2 |
| 7988724 | Salahieh et al. | Aug 2011 | B2 |
| 8021421 | Fogarty et al. | Sep 2011 | B2 |
| 8052749 | Salahieh et al. | Nov 2011 | B2 |
| 8052750 | Tuval et al. | Nov 2011 | B2 |
| 8062355 | Figulla et al. | Nov 2011 | B2 |
| 8070800 | Lock et al. | Dec 2011 | B2 |
| 8075615 | Eberhardt et al. | Dec 2011 | B2 |
| 8096985 | Legaspi et al. | Jan 2012 | B2 |
| 8147541 | Forster et al. | Apr 2012 | B2 |
| 8147542 | Maisano et al. | Apr 2012 | B2 |
| 8182528 | Salahieh et al. | May 2012 | B2 |
| 8216256 | Raschdorf et al. | Jul 2012 | B2 |
| 8236049 | Rowe et al. | Aug 2012 | B2 |
| 8241351 | Cabiri | Aug 2012 | B2 |
| 8251977 | Partlett | Aug 2012 | B2 |
| 8252050 | Maisano et al. | Aug 2012 | B2 |
| 8287584 | Salahieh et al. | Oct 2012 | B2 |
| 8313526 | Hoffman et al. | Nov 2012 | B2 |
| 8323241 | Salahieh et al. | Dec 2012 | B2 |
| 8323336 | Hill et al. | Dec 2012 | B2 |
| 8328868 | Paul et al. | Dec 2012 | B2 |
| 8343213 | Salahieh et al. | Jan 2013 | B2 |
| 8348995 | Tuval et al. | Jan 2013 | B2 |
| 8348996 | Tuval et al. | Jan 2013 | B2 |
| 8366767 | Zhang | Feb 2013 | B2 |
| 8403981 | Forster et al. | Mar 2013 | B2 |
| 8403983 | Quadri et al. | Mar 2013 | B2 |
| 8414643 | Tuval et al. | Apr 2013 | B2 |
| 8414644 | Quadri et al. | Apr 2013 | B2 |
| 8414645 | Dwork et al. | Apr 2013 | B2 |
| 8425593 | Braido et al. | Apr 2013 | B2 |
| 8449599 | Chau et al. | May 2013 | B2 |
| 8454686 | Alkhatib | Jun 2013 | B2 |
| 8465541 | Dwork | Jun 2013 | B2 |
| 8500800 | Maisano et al. | Aug 2013 | B2 |
| 8512401 | Murray et al. | Aug 2013 | B2 |
| 8523881 | Cabiri et al. | Sep 2013 | B2 |
| 8545553 | Zipory et al. | Oct 2013 | B2 |
| 8556963 | Tremulis et al. | Oct 2013 | B2 |
| 8562645 | Stone et al. | Oct 2013 | B2 |
| 8562673 | Yeung et al. | Oct 2013 | B2 |
| 8579962 | Salahieh et al. | Nov 2013 | B2 |
| 8603157 | Seguin et al. | Dec 2013 | B2 |
| 8603160 | Salahieh et al. | Dec 2013 | B2 |
| 8623075 | Murray et al. | Jan 2014 | B2 |
| 8628570 | Seguin | Jan 2014 | B2 |
| 8641727 | Starksen et al. | Feb 2014 | B2 |
| 8652202 | Alon et al. | Feb 2014 | B2 |
| 8652203 | Quadri et al. | Feb 2014 | B2 |
| 8657872 | Seguin | Feb 2014 | B2 |
| 8685086 | Navia et al. | Apr 2014 | B2 |
| 8696693 | Najafi et al. | Apr 2014 | B2 |
| 8715342 | Zipory et al. | May 2014 | B2 |
| 8740976 | Tran et al. | Jun 2014 | B2 |
| 8784479 | Antonsson et al. | Jul 2014 | B2 |
| 8790367 | Nguyen et al. | Jul 2014 | B2 |
| 8808368 | Maisano et al. | Aug 2014 | B2 |
| 8828078 | Salahieh et al. | Sep 2014 | B2 |
| 8834564 | Tuval et al. | Sep 2014 | B2 |
| 8840663 | Salahieh et al. | Sep 2014 | B2 |
| 8840664 | Karapetian et al. | Sep 2014 | B2 |
| 8845588 | Bruszewski | Sep 2014 | B2 |
| 8852271 | Murray et al. | Oct 2014 | B2 |
| 8876893 | Dwork et al. | Nov 2014 | B2 |
| 8876894 | Tuval et al. | Nov 2014 | B2 |
| 8876895 | Tuval et al. | Nov 2014 | B2 |
| 8900294 | Paniagua et al. | Dec 2014 | B2 |
| 8911494 | Hammer et al. | Dec 2014 | B2 |
| 8920369 | Salahieh et al. | Dec 2014 | B2 |
| 8926690 | Kovalsky | Jan 2015 | B2 |
| 8926696 | Cabiri et al. | Jan 2015 | B2 |
| 8926697 | Gross et al. | Jan 2015 | B2 |
| 8940002 | Goertzen | Jan 2015 | B2 |
| 8940044 | Hammer et al. | Jan 2015 | B2 |
| 8951299 | Paul et al. | Feb 2015 | B2 |
| 8986371 | Quill et al. | Mar 2015 | B2 |
| 8998980 | Shipley et al. | Apr 2015 | B2 |
| 9005273 | Salahleh et al. | Apr 2015 | B2 |
| 9011515 | Schweich et al. | Apr 2015 | B2 |
| 9011523 | Seguin | Apr 2015 | B2 |
| 9011530 | Reich et al. | Apr 2015 | B2 |
| 9017408 | Siegal et al. | Apr 2015 | B2 |
| 9023100 | Quadri et al. | May 2015 | B2 |
| 9034032 | McLean et al. | May 2015 | B2 |
| 9039757 | McLean et al. | May 2015 | B2 |
| 9056009 | Keränen | Jun 2015 | B2 |
| 9061120 | Osypka et al. | Jun 2015 | B2 |
| 9078747 | Conklin | Jul 2015 | B2 |
| 9095431 | Yu et al. | Aug 2015 | B2 |
| 9119719 | Zipory et al. | Sep 2015 | B2 |
| 9125739 | Paniagua et al. | Sep 2015 | B2 |
| 9125740 | Morriss et al. | Sep 2015 | B2 |
| 9155619 | Liu et al. | Oct 2015 | B2 |
| 9168129 | Valdez et al. | Oct 2015 | B2 |
| 9168131 | Yohanan | Oct 2015 | B2 |
| 9173713 | Hart et al. | Nov 2015 | B2 |
| 9173737 | Hill et al. | Nov 2015 | B2 |
| 9180006 | Keränen | Nov 2015 | B2 |
| 9226823 | Dwork | Jan 2016 | B2 |
| 9232995 | Kovalsky | Jan 2016 | B2 |
| 9277994 | Miller et al. | Mar 2016 | B2 |
| 9289297 | Wilson et al. | Mar 2016 | B2 |
| 9295547 | Costello et al. | Mar 2016 | B2 |
| 9301756 | Wardle | Apr 2016 | B2 |
| 9301836 | Buchbinder et al. | Apr 2016 | B2 |
| 9320597 | Savage et al. | Apr 2016 | B2 |
| 9339380 | Quadri | May 2016 | B2 |
| 9343224 | Zilbershlag | May 2016 | B2 |
| 9358110 | Paul et al. | Jun 2016 | B2 |
| 9414915 | Lombardi et al. | Aug 2016 | B2 |
| 9427315 | Schweich et al. | Aug 2016 | B2 |
| 9439757 | Wallace et al. | Sep 2016 | B2 |
| 9468525 | Kovalsky | Oct 2016 | B2 |
| 9474606 | Zipory et al. | Oct 2016 | B2 |
| 9474840 | Siess | Oct 2016 | B2 |
| 9480559 | Vidlund et al. | Nov 2016 | B2 |
| 9480560 | Quadri | Nov 2016 | B2 |
| 9492273 | Wallace et al. | Nov 2016 | B2 |
| 9526487 | Rahmani | Dec 2016 | B2 |
| 9526609 | Salahieh et al. | Dec 2016 | B2 |
| 9532868 | Braido | Jan 2017 | B2 |
| 9532870 | Cooper et al. | Jan 2017 | B2 |
| 9561102 | Rust et al. | Feb 2017 | B2 |
| 9579198 | Deem et al. | Feb 2017 | B2 |
| 9636224 | Zipory et al. | May 2017 | B2 |
| 9636481 | Campbell et al. | May 2017 | B2 |
| 9662202 | Quill et al. | May 2017 | B2 |
| 9662206 | Börtlein et al. | May 2017 | B2 |
| 9662209 | Gross et al. | May 2017 | B2 |
| 9675454 | Vidlund et al. | Jun 2017 | B2 |
| 9681952 | Hacohen et al. | Jun 2017 | B2 |
| 9687343 | Börtlein et al. | Jun 2017 | B2 |
| 9724192 | Sheps et al. | Aug 2017 | B2 |
| 9730790 | Quadri et al. | Aug 2017 | B2 |
| 9730793 | Reich et al. | Aug 2017 | B2 |
| 9744031 | Girard et al. | Aug 2017 | B2 |
| 9744038 | Dahlgren et al. | Aug 2017 | B2 |
| 9750605 | Ganesan et al. | Sep 2017 | B2 |
| 9763779 | Börtlein et al. | Sep 2017 | B2 |
| 9763780 | Morriss et al. | Sep 2017 | B2 |
| 9814611 | Cartledge et al. | Nov 2017 | B2 |
| 9827090 | Hill et al. | Nov 2017 | B2 |
| 9861480 | Zakai et al. | Jan 2018 | B2 |
| 9867700 | Bakis et al. | Jan 2018 | B2 |
| 9867702 | Keränen et al. | Jan 2018 | B2 |
| 9877833 | Bishop et al. | Jan 2018 | B1 |
| 9883941 | Hastings et al. | Feb 2018 | B2 |
| 9889003 | Börtlein et al. | Feb 2018 | B2 |
| 9895221 | Vidlund | Feb 2018 | B2 |
| 9895222 | Zeng et al. | Feb 2018 | B2 |
| 9901444 | Valdez et al. | Feb 2018 | B2 |
| 9918840 | Reich et al. | Mar 2018 | B2 |
| D815744 | Ratz et al. | Apr 2018 | S |
| 9949825 | Braido et al. | Apr 2018 | B2 |
| 9949828 | Sheps et al. | Apr 2018 | B2 |
| 9950142 | Eversull et al. | Apr 2018 | B2 |
| 9968452 | Sheps et al. | May 2018 | B2 |
| 9974647 | Ganesan | May 2018 | B2 |
| 9974650 | Nguyen-Thien-Nhon et al. | May 2018 | B2 |
| 9999502 | Nasr et al. | Jun 2018 | B2 |
| 9999504 | Czyscon et al. | Jun 2018 | B2 |
| 10004599 | Rabito et al. | Jun 2018 | B2 |
| 10016271 | Morriss et al. | Jul 2018 | B2 |
| 10016272 | Spence et al. | Jul 2018 | B2 |
| 10028832 | Quill et al. | Jul 2018 | B2 |
| 10029037 | Muller et al. | Jul 2018 | B2 |
| 10034747 | Harewood | Jul 2018 | B2 |
| 10034749 | Spence et al. | Jul 2018 | B2 |
| 10039637 | Maimon et al. | Aug 2018 | B2 |
| 10045846 | Bonyuet et al. | Aug 2018 | B2 |
| 10052198 | Chau et al. | Aug 2018 | B2 |
| 10052199 | Spence et al. | Aug 2018 | B2 |
| 10058318 | Tegzes | Aug 2018 | B2 |
| 10058321 | Sampson et al. | Aug 2018 | B2 |
| 10058424 | Cooper | Aug 2018 | B2 |
| 10064719 | Börtlein et al. | Sep 2018 | B2 |
| 10070954 | Braido et al. | Sep 2018 | B2 |
| 10092400 | Jimenez et al. | Oct 2018 | B2 |
| 10098734 | Hoang | Oct 2018 | B2 |
| 10105217 | Keränen | Oct 2018 | B2 |
| 10105224 | Buchbinder et al. | Oct 2018 | B2 |
| 10117744 | Ratz | Nov 2018 | B2 |
| 10130464 | Meiri et al. | Nov 2018 | B2 |
| 10130471 | Keränen et al. | Nov 2018 | B2 |
| 10143552 | Wallace et al. | Dec 2018 | B2 |
| 10149756 | Quadri | Dec 2018 | B2 |
| 10149759 | Naor | Dec 2018 | B2 |
| 10172708 | Anderson | Jan 2019 | B2 |
| 10172711 | Keränen | Jan 2019 | B2 |
| 10179042 | Braido et al. | Jan 2019 | B2 |
| 10179044 | Ratz | Jan 2019 | B2 |
| 10188514 | Nasr | Jan 2019 | B2 |
| 10195021 | Keränen et al. | Feb 2019 | B2 |
| 10195025 | Levi et al. | Feb 2019 | B2 |
| 10195027 | Nasr | Feb 2019 | B2 |
| 10195028 | Hosmer et al. | Feb 2019 | B2 |
| 10195029 | Keränen | Feb 2019 | B2 |
| 10201418 | Biadillah et al. | Feb 2019 | B2 |
| 10206775 | Kovalsky et al. | Feb 2019 | B2 |
| 10213307 | Dwork et al. | Feb 2019 | B2 |
| 10226330 | Spence et al. | Mar 2019 | B2 |
| 10226334 | Rowe et al. | Mar 2019 | B2 |
| 10226339 | Spence et al. | Mar 2019 | B2 |
| 10238489 | Conklin | Mar 2019 | B2 |
| 10251749 | Zerkowski et al. | Apr 2019 | B2 |
| 10258464 | Delaloye et al. | Apr 2019 | B2 |
| 10258468 | Deem et al. | Apr 2019 | B2 |
| 10265169 | Desrosiers et al. | Apr 2019 | B2 |
| 10271950 | Neustadter | Apr 2019 | B2 |
| 10299917 | Morriss et al. | May 2019 | B2 |
| 10299921 | Dale et al. | May 2019 | B2 |
| 10314701 | Von Segesser et al. | Jun 2019 | B2 |
| 10321988 | Gorman et al. | Jun 2019 | B2 |
| 10321989 | Keränen | Jun 2019 | B2 |
| 10327743 | St. Goar et al. | Jun 2019 | B2 |
| 10327766 | Zerkowski et al. | Jun 2019 | B2 |
| 10335277 | Crisostomo et al. | Jul 2019 | B2 |
| 10338724 | Zhao | Jul 2019 | B2 |
| 10350066 | Cooper et al. | Jul 2019 | B2 |
| 10357351 | Cooper et al. | Jul 2019 | B2 |
| 10357634 | Simmons et al. | Jul 2019 | B2 |
| 10363130 | Armer et al. | Jul 2019 | B2 |
| 10363131 | Eidenschink et al. | Jul 2019 | B2 |
| 10368986 | Gosal et al. | Aug 2019 | B2 |
| 10368990 | Noe et al. | Aug 2019 | B2 |
| 10376266 | Herman et al. | Aug 2019 | B2 |
| 10376360 | Bruchman et al. | Aug 2019 | B2 |
| 10376363 | Quadri et al. | Aug 2019 | B2 |
| 10398547 | Li et al. | Sep 2019 | B2 |
| 10426605 | Ma | Oct 2019 | B2 |
| 10426608 | Salahieh et al. | Oct 2019 | B2 |
| 10433961 | McLean | Oct 2019 | B2 |
| 10470881 | Noe et al. | Nov 2019 | B2 |
| 10478291 | Nguyen et al. | Nov 2019 | B2 |
| 10500048 | Khairkhahan et al. | Dec 2019 | B2 |
| 10507104 | Zhang et al. | Dec 2019 | B2 |
| 10512541 | Zerkowski et al. | Dec 2019 | B2 |
| 10524901 | Quadri et al. | Jan 2020 | B2 |
| 10548729 | Zipory et al. | Feb 2020 | B2 |
| 10568737 | Noe et al. | Feb 2020 | B2 |
| 10575951 | Johnson et al. | Mar 2020 | B2 |
| 10603165 | Maimon et al. | Mar 2020 | B2 |
| 10639143 | Oba | May 2020 | B2 |
| 10639154 | Seguin | May 2020 | B2 |
| 10653524 | Khairkhahan et al. | May 2020 | B2 |
| 10660753 | Pham et al. | May 2020 | B2 |
| 10687938 | Patel et al. | Jun 2020 | B2 |
| 10695160 | Lashinski et al. | Jun 2020 | B2 |
| 10702386 | Khairkhahan et al. | Jul 2020 | B2 |
| 10709552 | Backus et al. | Jul 2020 | B2 |
| 10716662 | Delaloye et al. | Jul 2020 | B2 |
| 10722351 | Griffin et al. | Jul 2020 | B2 |
| 10722352 | Spence | Jul 2020 | B2 |
| 10722353 | Levi | Jul 2020 | B2 |
| 10729542 | Howard et al. | Aug 2020 | B2 |
| 10743991 | Brown | Aug 2020 | B2 |
| 10751180 | Schewel | Aug 2020 | B2 |
| 10751184 | Reich et al. | Aug 2020 | B2 |
| 10765514 | Iflah et al. | Sep 2020 | B2 |
| 10813749 | Nguyen et al. | Oct 2020 | B2 |
| 10828153 | Noe et al. | Nov 2020 | B2 |
| 10856970 | Tuval et al. | Dec 2020 | B2 |
| 10869755 | Granada et al. | Dec 2020 | B2 |
| 10888420 | Bateman et al. | Jan 2021 | B2 |
| 10888421 | Hariton | Jan 2021 | B2 |
| 10912644 | Argento et al. | Feb 2021 | B2 |
| 10973629 | Levi et al. | Apr 2021 | B2 |
| 10973630 | Torrianni et al. | Apr 2021 | B2 |
| 11007057 | Pham et al. | May 2021 | B2 |
| 11020221 | Arcaro et al. | Jun 2021 | B2 |
| 11039922 | Konno | Jun 2021 | B2 |
| 11051934 | Cooper | Jul 2021 | B2 |
| 11051935 | Schweich, Jr. | Jul 2021 | B2 |
| 11147670 | Hayoz et al. | Oct 2021 | B2 |
| 11234818 | Zerkowski et al. | Feb 2022 | B2 |
| 11547563 | Keränen et al. | Jan 2023 | B2 |
| 11759318 | Vidlund | Sep 2023 | B2 |
| 20020173841 | Ortiz et al. | Nov 2002 | A1 |
| 20030114913 | Spenser | Jun 2003 | A1 |
| 20030233142 | Morales et al. | Dec 2003 | A1 |
| 20040039442 | St. Goar et al. | Feb 2004 | A1 |
| 20040044350 | Martin et al. | Mar 2004 | A1 |
| 20050137686 | Salahieh et al. | Jun 2005 | A1 |
| 20050137687 | Salahieh et al. | Jun 2005 | A1 |
| 20050137691 | Salahieh et al. | Jun 2005 | A1 |
| 20050137694 | Haug et al. | Jun 2005 | A1 |
| 20050137696 | Salahieh et al. | Jun 2005 | A1 |
| 20050165344 | Dobak | Jul 2005 | A1 |
| 20050240202 | Shennib et al. | Oct 2005 | A1 |
| 20050277839 | Alderman et al. | Dec 2005 | A1 |
| 20060009841 | McGuckin et al. | Jan 2006 | A1 |
| 20060052821 | Abbot et al. | Mar 2006 | A1 |
| 20060074484 | Huber | Apr 2006 | A1 |
| 20060178700 | Quinn | Aug 2006 | A1 |
| 20060195134 | Crittenden | Aug 2006 | A1 |
| 20060217762 | Maahs et al. | Sep 2006 | A1 |
| 20060259136 | Nguyen et al. | Nov 2006 | A1 |
| 20060293698 | Douk | Dec 2006 | A1 |
| 20070027533 | Douk | Feb 2007 | A1 |
| 20070038292 | Danielpour | Feb 2007 | A1 |
| 20070051377 | Douk et al. | Mar 2007 | A1 |
| 20070055206 | To et al. | Mar 2007 | A1 |
| 20070118151 | Davidson | May 2007 | A1 |
| 20070142907 | Moaddeb et al. | Jun 2007 | A1 |
| 20070185572 | Solem et al. | Aug 2007 | A1 |
| 20070255396 | Douk et al. | Nov 2007 | A1 |
| 20070293724 | Saadat et al. | Dec 2007 | A1 |
| 20070293943 | Quinn | Dec 2007 | A1 |
| 20080004696 | Vesely | Jan 2008 | A1 |
| 20080004697 | Lichtenstein et al. | Jan 2008 | A1 |
| 20080200980 | Robin et al. | Aug 2008 | A1 |
| 20080208327 | Rowe | Aug 2008 | A1 |
| 20080275503 | Spence et al. | Nov 2008 | A1 |
| 20080275540 | Wen | Nov 2008 | A1 |
| 20090030504 | Weber et al. | Jan 2009 | A1 |
| 20090088836 | Bishop et al. | Apr 2009 | A1 |
| 20090093826 | Warder-Gabaldon | Apr 2009 | A1 |
| 20090138079 | Tuval et al. | May 2009 | A1 |
| 20090157174 | Yoganathan et al. | Jun 2009 | A1 |
| 20090192601 | Rafiee | Jul 2009 | A1 |
| 20090209950 | Starksen | Aug 2009 | A1 |
| 20090222026 | Rothstein et al. | Sep 2009 | A1 |
| 20090276040 | Rowe et al. | Nov 2009 | A1 |
| 20090299471 | Keranen | Dec 2009 | A1 |
| 20100010520 | Takahashi et al. | Jan 2010 | A1 |
| 20100049239 | McGuckin, Jr. et al. | Feb 2010 | A1 |
| 20100076497 | Zwirkoski | Mar 2010 | A1 |
| 20100076549 | Keidar et al. | Mar 2010 | A1 |
| 20100094406 | Leprince et al. | Apr 2010 | A1 |
| 20100185172 | Fabro | Jul 2010 | A1 |
| 20100198056 | Fabro et al. | Aug 2010 | A1 |
| 20100198192 | Serina et al. | Aug 2010 | A1 |
| 20100198208 | Napp et al. | Aug 2010 | A1 |
| 20100217385 | Thompson et al. | Aug 2010 | A1 |
| 20100312333 | Navia et al. | Dec 2010 | A1 |
| 20110022164 | Quinn et al. | Jan 2011 | A1 |
| 20110040366 | Goetz et al. | Feb 2011 | A1 |
| 20110046600 | Crank | Feb 2011 | A1 |
| 20110208298 | Tuval | Aug 2011 | A1 |
| 20110224785 | Hacohen | Sep 2011 | A1 |
| 20110245911 | Quill et al. | Oct 2011 | A1 |
| 20110288637 | De Marchena | Nov 2011 | A1 |
| 20110295363 | Girard | Dec 2011 | A1 |
| 20110313515 | Quadri et al. | Dec 2011 | A1 |
| 20110319989 | Lane et al. | Dec 2011 | A1 |
| 20120022633 | Olson et al. | Jan 2012 | A1 |
| 20120053680 | Bolling et al. | Mar 2012 | A1 |
| 20120053682 | Kovalsky | Mar 2012 | A1 |
| 20120143316 | Seguin et al. | Jun 2012 | A1 |
| 20120197388 | Khairkhahan et al. | Aug 2012 | A1 |
| 20120203333 | McGuckin, Jr. et al. | Aug 2012 | A1 |
| 20120221101 | Moaddeb et al. | Aug 2012 | A1 |
| 20120277734 | Geotz et al. | Nov 2012 | A1 |
| 20120277853 | Rothstein | Nov 2012 | A1 |
| 20130006352 | Yaron | Jan 2013 | A1 |
| 20130023985 | Khairkhahan et al. | Jan 2013 | A1 |
| 20130035758 | Seguin et al. | Feb 2013 | A1 |
| 20130079873 | Migliazza et al. | Mar 2013 | A1 |
| 20130116779 | Weber | May 2013 | A1 |
| 20130123912 | Tung et al. | May 2013 | A1 |
| 20130172992 | Gross et al. | Jul 2013 | A1 |
| 20130253643 | Rolando et al. | Sep 2013 | A1 |
| 20130274873 | Delaloye et al. | Oct 2013 | A1 |
| 20130282113 | Punga | Oct 2013 | A1 |
| 20130304200 | McLean | Nov 2013 | A1 |
| 20130325110 | Khalil et al. | Dec 2013 | A1 |
| 20130331931 | Gregg | Dec 2013 | A1 |
| 20140005768 | Thomas et al. | Jan 2014 | A1 |
| 20140031928 | Murphy et al. | Jan 2014 | A1 |
| 20140081154 | Toth | May 2014 | A1 |
| 20140194983 | Kovalsky | Jul 2014 | A1 |
| 20140200649 | Essinger et al. | Jul 2014 | A1 |
| 20140222136 | Geist | Aug 2014 | A1 |
| 20140222142 | Kovalsky | Aug 2014 | A1 |
| 20140228943 | Stigall et al. | Aug 2014 | A1 |
| 20140249621 | Eidenschink | Sep 2014 | A1 |
| 20140257467 | Lane et al. | Sep 2014 | A1 |
| 20140277382 | Dolan et al. | Sep 2014 | A1 |
| 20140277409 | Börtlein et al. | Sep 2014 | A1 |
| 20140277427 | Ratz | Sep 2014 | A1 |
| 20140296966 | Braido | Oct 2014 | A1 |
| 20140324163 | Keränen et al. | Oct 2014 | A1 |
| 20140350669 | Gillespie | Nov 2014 | A1 |
| 20150005764 | Hanson et al. | Jan 2015 | A1 |
| 20150005874 | Vidlund | Jan 2015 | A1 |
| 20150018876 | Ewers et al. | Jan 2015 | A1 |
| 20150051709 | Vasquez et al. | Feb 2015 | A1 |
| 20150094802 | Buchbinder | Apr 2015 | A1 |
| 20150134055 | Spence et al. | May 2015 | A1 |
| 20150173897 | Raanani et al. | Jun 2015 | A1 |
| 20150250480 | Featherstone | Sep 2015 | A1 |
| 20150257879 | Bortlein | Sep 2015 | A1 |
| 20150265403 | Keränen | Sep 2015 | A1 |
| 20150272737 | Dale et al. | Oct 2015 | A1 |
| 20150297346 | Duffy et al. | Oct 2015 | A1 |
| 20150305863 | Gray et al. | Oct 2015 | A1 |
| 20150328000 | Ratz et al. | Nov 2015 | A1 |
| 20150335290 | Hunter | Nov 2015 | A1 |
| 20150335426 | Lim et al. | Nov 2015 | A1 |
| 20150351735 | Keränen et al. | Dec 2015 | A1 |
| 20150351908 | Keränen et al. | Dec 2015 | A1 |
| 20150351911 | Keränen et al. | Dec 2015 | A1 |
| 20160089126 | Guo | Mar 2016 | A1 |
| 20160095705 | Keränen et al. | Apr 2016 | A1 |
| 20160113764 | Sheahan et al. | Apr 2016 | A1 |
| 20160113766 | Ganesan | Apr 2016 | A1 |
| 20160143689 | Ditter | May 2016 | A1 |
| 20160143731 | Backus et al. | May 2016 | A1 |
| 20160151153 | Sandstrom | Jun 2016 | A1 |
| 20160166380 | Seguin et al. | Jun 2016 | A1 |
| 20160206853 | Bolduc et al. | Jul 2016 | A1 |
| 20160228247 | Maimon et al. | Aug 2016 | A1 |
| 20160235526 | Lashinski et al. | Aug 2016 | A1 |
| 20160235529 | Ma et al. | Aug 2016 | A1 |
| 20160324637 | Hlavka et al. | Nov 2016 | A1 |
| 20160324639 | Nguyen et al. | Nov 2016 | A1 |
| 20160331523 | Chau et al. | Nov 2016 | A1 |
| 20160346080 | Righini et al. | Dec 2016 | A1 |
| 20170056163 | Tayeb et al. | Mar 2017 | A1 |
| 20170071732 | Conklin et al. | Mar 2017 | A1 |
| 20170079790 | Vidlund et al. | Mar 2017 | A1 |
| 20170095328 | Cooper | Apr 2017 | A1 |
| 20170112624 | Patel | Apr 2017 | A1 |
| 20170119524 | Salahich et al. | May 2017 | A1 |
| 20170128203 | Zhang et al. | May 2017 | A1 |
| 20170156723 | Keating et al. | Jun 2017 | A1 |
| 20170165054 | Benson | Jun 2017 | A1 |
| 20170165057 | Morriss et al. | Jun 2017 | A9 |
| 20170189177 | Schweich et al. | Jul 2017 | A1 |
| 20170216025 | Nitzan et al. | Aug 2017 | A1 |
| 20170245850 | Call et al. | Aug 2017 | A1 |
| 20170258585 | Marquez et al. | Sep 2017 | A1 |
| 20170273788 | O'Carroll et al. | Sep 2017 | A1 |
| 20170273789 | Yaron et al. | Sep 2017 | A1 |
| 20170281341 | Lim et al. | Oct 2017 | A1 |
| 20170311937 | Bambury et al. | Nov 2017 | A1 |
| 20170348099 | Mendelson et al. | Dec 2017 | A1 |
| 20180014931 | Morriss | Jan 2018 | A1 |
| 20180021546 | McDermott et al. | Jan 2018 | A1 |
| 20180049873 | Manash et al. | Feb 2018 | A1 |
| 20180055628 | Patel et al. | Mar 2018 | A1 |
| 20180092763 | Dagan et al. | Apr 2018 | A1 |
| 20180110622 | Gregg et al. | Apr 2018 | A1 |
| 20180116790 | Ratz et al. | May 2018 | A1 |
| 20180125648 | Nasr | May 2018 | A1 |
| 20180125649 | Nasr | May 2018 | A1 |
| 20180125650 | Nasr | May 2018 | A1 |
| 20180125651 | Nasr | May 2018 | A1 |
| 20180133003 | Levi | May 2018 | A1 |
| 20180177592 | Benichou et al. | Jun 2018 | A1 |
| 20180177594 | Patel et al. | Jun 2018 | A1 |
| 20180206982 | Haivatov et al. | Jul 2018 | A1 |
| 20180206986 | Noe | Jul 2018 | A1 |
| 20180206992 | Brown | Jul 2018 | A1 |
| 20180207395 | Bulman et al. | Jul 2018 | A1 |
| 20180214267 | Lally et al. | Aug 2018 | A1 |
| 20180214270 | Subramanian et al. | Aug 2018 | A1 |
| 20180221014 | Darabian | Aug 2018 | A1 |
| 20180228608 | Sheps et al. | Aug 2018 | A1 |
| 20180228610 | Lashinski et al. | Aug 2018 | A1 |
| 20180235443 | Smith et al. | Aug 2018 | A1 |
| 20180250126 | O'Connor et al. | Sep 2018 | A1 |
| 20180250132 | Ketai et al. | Sep 2018 | A1 |
| 20180263764 | Manash et al. | Sep 2018 | A1 |
| 20180280171 | Gloss et al. | Oct 2018 | A1 |
| 20180289473 | Rajagopal et al. | Oct 2018 | A1 |
| 20180289474 | Rajagopal et al. | Oct 2018 | A1 |
| 20180289478 | Quill | Oct 2018 | A1 |
| 20180289480 | D'ambra et al. | Oct 2018 | A1 |
| 20180289485 | Rajagopal et al. | Oct 2018 | A1 |
| 20180296335 | Miyashiro | Oct 2018 | A1 |
| 20180296338 | Rabito et al. | Oct 2018 | A1 |
| 20180296341 | Noe | Oct 2018 | A1 |
| 20180318079 | Patel et al. | Nov 2018 | A1 |
| 20180325665 | Gurovich | Nov 2018 | A1 |
| 20180333259 | Dibie | Nov 2018 | A1 |
| 20180344303 | Bambury et al. | Dec 2018 | A1 |
| 20180344454 | Mauch et al. | Dec 2018 | A1 |
| 20180344459 | Spence et al. | Dec 2018 | A1 |
| 20180344971 | Suzuki et al. | Dec 2018 | A1 |
| 20180360600 | Zhuang et al. | Dec 2018 | A1 |
| 20180368830 | O'Carroll et al. | Dec 2018 | A1 |
| 20190000615 | Tayeb | Jan 2019 | A1 |
| 20190000625 | O'Carroll et al. | Jan 2019 | A1 |
| 20190008635 | Francis et al. | Jan 2019 | A1 |
| 20190008639 | Landon et al. | Jan 2019 | A1 |
| 20190008640 | Cooper et al. | Jan 2019 | A1 |
| 20190015205 | Rajagopal et al. | Jan 2019 | A1 |
| 20190021859 | O'Carrol et al. | Jan 2019 | A1 |
| 20190046315 | Gao et al. | Feb 2019 | A1 |
| 20190053894 | Levi et al. | Feb 2019 | A1 |
| 20190053895 | Levi | Feb 2019 | A1 |
| 20190053898 | Maimon et al. | Feb 2019 | A1 |
| 20190053899 | Levi | Feb 2019 | A1 |
| 20190053903 | Rohl et al. | Feb 2019 | A1 |
| 20190060068 | Cope et al. | Feb 2019 | A1 |
| 20190060069 | Maimon et al. | Feb 2019 | A1 |
| 20190060071 | Lane et al. | Feb 2019 | A1 |
| 20190076244 | Yohanan et al. | Mar 2019 | A1 |
| 20190076664 | Ollivier | Mar 2019 | A1 |
| 20190091014 | Arcaro | Mar 2019 | A1 |
| 20190117392 | Quadri et al. | Apr 2019 | A1 |
| 20190133756 | Zhang et al. | May 2019 | A1 |
| 20190133757 | Zhang et al. | May 2019 | A1 |
| 20190142589 | Basude | May 2019 | A1 |
| 20190159770 | Rohl et al. | May 2019 | A1 |
| 20190160292 | Peichel et al. | May 2019 | A1 |
| 20190167425 | Reich et al. | Jun 2019 | A1 |
| 20190183649 | Allen et al. | Jun 2019 | A1 |
| 20190192288 | Levi et al. | Jun 2019 | A1 |
| 20190192296 | Schwartz et al. | Jun 2019 | A1 |
| 20190201191 | McLean et al. | Jul 2019 | A1 |
| 20190209311 | Zhang et al. | Jul 2019 | A1 |
| 20190209312 | Zhang et al. | Jul 2019 | A1 |
| 20190209313 | Zhang et al. | Jul 2019 | A1 |
| 20190209314 | Zhang et al. | Jul 2019 | A1 |
| 20190209315 | Zhang et al. | Jul 2019 | A1 |
| 20190209316 | Zhang et al. | Jul 2019 | A1 |
| 20190209317 | Zhang et al. | Jul 2019 | A1 |
| 20190209318 | Zhang et al. | Jul 2019 | A1 |
| 20190209320 | Drasler et al. | Jul 2019 | A1 |
| 20190231520 | Desrosiers et al. | Aug 2019 | A1 |
| 20190240023 | Spence et al. | Aug 2019 | A1 |
| 20190246916 | Kuraguntla et al. | Aug 2019 | A1 |
| 20190254816 | Anderson et al. | Aug 2019 | A1 |
| 20190261995 | Goldfarb et al. | Aug 2019 | A1 |
| 20190261996 | Goldfarb et al. | Aug 2019 | A1 |
| 20190261997 | Goldfarb et al. | Aug 2019 | A1 |
| 20190262129 | Cooper et al. | Aug 2019 | A1 |
| 20190282237 | Goldfarb et al. | Sep 2019 | A1 |
| 20190328515 | Peterson | Oct 2019 | A1 |
| 20190328518 | Neumann | Oct 2019 | A1 |
| 20190336282 | Christianson et al. | Nov 2019 | A1 |
| 20190343625 | Gharib et al. | Nov 2019 | A1 |
| 20190365530 | Hoang et al. | Dec 2019 | A1 |
| 20190374337 | Zamani et al. | Dec 2019 | A1 |
| 20190374342 | Gregg et al. | Dec 2019 | A1 |
| 20200000579 | Manash et al. | Jan 2020 | A1 |
| 20200000586 | Tian et al. | Jan 2020 | A1 |
| 20200008936 | Cheema et al. | Jan 2020 | A1 |
| 20200022811 | Griswold et al. | Jan 2020 | A1 |
| 20200054453 | Zerkowski et al. | Feb 2020 | A1 |
| 20200060813 | Nguyen et al. | Feb 2020 | A1 |
| 20200060820 | Ben-Zvi et al. | Feb 2020 | A1 |
| 20200060852 | Argento et al. | Feb 2020 | A1 |
| 20200069415 | Bialas | Mar 2020 | A1 |
| 20200078000 | Rajagopal et al. | Mar 2020 | A1 |
| 20200093601 | Neustadter | Mar 2020 | A1 |
| 20200107932 | Rabito et al. | Apr 2020 | A1 |
| 20200107933 | Oba | Apr 2020 | A1 |
| 20200113586 | Karasic et al. | Apr 2020 | A1 |
| 20200113685 | Miller et al. | Apr 2020 | A1 |
| 20200113696 | Ekvall et al. | Apr 2020 | A1 |
| 20200138575 | Tuval | May 2020 | A1 |
| 20200139082 | Matlock | May 2020 | A1 |
| 20200178977 | Coleman et al. | Jun 2020 | A1 |
| 20200188107 | Gloss et al. | Jun 2020 | A1 |
| 20200205800 | Gilmore et al. | Jul 2020 | A1 |
| 20200205969 | Hacohen | Jul 2020 | A1 |
| 20200205974 | Zerkowski et al. | Jul 2020 | A1 |
| 20200205975 | Khairkhahan | Jul 2020 | A1 |
| 20200205979 | O'Carroll et al. | Jul 2020 | A1 |
| 20200214708 | Sharma | Jul 2020 | A1 |
| 20200229806 | Goldfarb et al. | Jul 2020 | A1 |
| 20200229918 | Pham et al. | Jul 2020 | A1 |
| 20200261220 | Argento et al. | Aug 2020 | A1 |
| 20200275921 | Gilmore et al. | Sep 2020 | A1 |
| 20200276017 | Subramanian et al. | Sep 2020 | A1 |
| 20200297489 | Bishop et al. | Sep 2020 | A1 |
| 20200297491 | Argento et al. | Sep 2020 | A1 |
| 20200323637 | Banai | Oct 2020 | A1 |
| 20200352705 | Heneghan et al. | Nov 2020 | A1 |
| 20200352706 | Campbell | Nov 2020 | A1 |
| 20200360139 | Hammer et al. | Nov 2020 | A1 |
| 20210022854 | Zhao et al. | Jan 2021 | A1 |
| 20210022860 | Lally et al. | Jan 2021 | A1 |
| 20210030536 | Kaleta | Feb 2021 | A1 |
| 20210121289 | Bruchman et al. | Apr 2021 | A1 |
| 20210128297 | Braido et al. | May 2021 | A1 |
| 20210145573 | Dasi et al. | May 2021 | A1 |
| 20210154009 | Argento et al. | May 2021 | A1 |
| 20210161688 | Shahriari | Jun 2021 | A1 |
| 20210177583 | Colavito et al. | Jun 2021 | A1 |
| 20210177584 | Levi et al. | Jun 2021 | A1 |
| 20210177587 | Braido | Jun 2021 | A1 |
| 20210186689 | Eidenschink et al. | Jun 2021 | A1 |
| 20210228343 | Scheinblum et al. | Jul 2021 | A1 |
| 20210315693 | Tabor | Oct 2021 | A1 |
| 20210338419 | Gifford, III | Nov 2021 | A1 |
| 20210378823 | Argento et al. | Dec 2021 | A1 |
| 20210386542 | Schankereli | Dec 2021 | A1 |
| 20210401572 | Nasar et al. | Dec 2021 | A1 |
| 20220054261 | Argento | Feb 2022 | A1 |
| 20220257373 | Yang et al. | Aug 2022 | A1 |
| 20220387755 | Higgins | Dec 2022 | A1 |
| 20220401214 | Saul | Dec 2022 | A1 |
| 20230028648 | Neuberger | Jan 2023 | A1 |
| 20230044256 | Salahieh | Feb 2023 | A1 |
| 20230105492 | Argento et al. | Apr 2023 | A1 |
| 20230118748 | Argento | Apr 2023 | A1 |
| 20230165679 | Boyd et al. | Jun 2023 | A1 |
| 20230225861 | Argento | Jul 2023 | A1 |
| 20230240839 | Corona | Aug 2023 | A1 |
| 20230277317 | Argento et al. | Sep 2023 | A1 |
| 20230320845 | Salahieh | Oct 2023 | A1 |
| 20240148497 | Bukin | May 2024 | A1 |
| 20240164895 | Mai | May 2024 | A1 |
| 20240285396 | Schwartz et al. | Aug 2024 | A1 |
| 20240293217 | Cartledge et al. | Sep 2024 | A1 |
| 20240374378 | Adamek-Bowers et al. | Nov 2024 | A1 |
| 20240390144 | Adamek-Bowers et al. | Nov 2024 | A1 |
| 20240415652 | Stearns | Dec 2024 | A1 |
| Number | Date | Country |
|---|---|---|
| 2012261727 | Oct 2015 | AU |
| 2019246822 | Aug 2020 | AU |
| 2020227034 | Sep 2020 | AU |
| PI0820603 | Jun 2020 | BR |
| 2979817 | Sep 2016 | CA |
| 2954826 | Oct 2019 | CA |
| 103764216 | Apr 2014 | CN |
| 103974670 | Aug 2014 | CN |
| 105358098 | Feb 2016 | CN |
| 107690323 | Feb 2018 | CN |
| 111110401 | May 2020 | CN |
| 111110403 | May 2020 | CN |
| 108601655 | Jun 2020 | CN |
| 111265335 | Jun 2020 | CN |
| 111278389 | Jun 2020 | CN |
| 111329541 | Jun 2020 | CN |
| 19857887 | May 2005 | DE |
| 102014102650 | Sep 2015 | DE |
| 1105181 | Feb 2004 | EP |
| 1432369 | Feb 2008 | EP |
| 2374415 | Oct 2011 | EP |
| 2907479 | Aug 2015 | EP |
| 3037064 | Jun 2016 | EP |
| 3158975 | Apr 2017 | EP |
| 3342355 | Jul 2018 | EP |
| 3395296 | Oct 2018 | EP |
| 3406225 | Nov 2018 | EP |
| 3417831 | Dec 2018 | EP |
| 3476366 | May 2019 | EP |
| 3482718 | May 2019 | EP |
| 2637607 | Oct 2019 | EP |
| 3554424 | Oct 2019 | EP |
| 324480981 | Feb 2020 | EP |
| 3639792 | Apr 2020 | EP |
| 3417831 | May 2020 | EP |
| 3649963 | May 2020 | EP |
| 2072027 | Jun 2020 | EP |
| 3441045 | Jul 2020 | EP |
| 3672528 | Jul 2020 | EP |
| 3554423 | Aug 2020 | EP |
| 3107498 | Sep 2020 | EP |
| 3570782 | Sep 2020 | EP |
| 3700467 | Sep 2020 | EP |
| 3705090 | Sep 2020 | EP |
| 3782585 | Feb 2021 | EP |
| H08131551 | May 1996 | JP |
| 2004154177 | Jun 2004 | JP |
| 2008018139 | Jan 2008 | JP |
| 2011506017 | Mar 2011 | JP |
| 2012531270 | Dec 2012 | JP |
| 2020515375 | May 2020 | JP |
| 2020517379 | Jun 2020 | JP |
| 2020520729 | Jul 2020 | JP |
| 6735294 | Aug 2020 | JP |
| 2020032237 | Mar 2020 | KR |
| 2020033349 | Mar 2020 | KR |
| 2020033350 | Mar 2020 | KR |
| 202027694 | Aug 2020 | TW |
| WO2007007873 | Jan 2007 | WO |
| WO2007081820 | Jul 2007 | WO |
| WO2009079475 | Jun 2009 | WO |
| WO-2010141847 | Dec 2010 | WO |
| WO2011025945 | Mar 2011 | WO |
| WO2012087842 | Jun 2012 | WO |
| WO2012145545 | Oct 2012 | WO |
| WO2013059747 | Apr 2013 | WO |
| WO2013190910 | Dec 2013 | WO |
| WO2015127264 | Aug 2015 | WO |
| WO2015173609 | Nov 2015 | WO |
| WO2015195823 | Dec 2015 | WO |
| WO2016052145 | Apr 2016 | WO |
| WO2016117169 | Jul 2016 | WO |
| WO2016183485 | Nov 2016 | WO |
| WO2017121193 | Jul 2017 | WO |
| WO2017151566 | Sep 2017 | WO |
| WO2017214098 | Dec 2017 | WO |
| WO-2018025260 | Feb 2018 | WO |
| WO2018039561 | Mar 2018 | WO |
| WO2018039589 | Mar 2018 | WO |
| WO2018112429 | Jun 2018 | WO |
| WO2018119304 | Jun 2018 | WO |
| WO2018178966 | Oct 2018 | WO |
| WO2018178967 | Oct 2018 | WO |
| WO2018187390 | Oct 2018 | WO |
| WO2018192197 | Oct 2018 | WO |
| WO2019010370 | Jan 2019 | WO |
| WO2019036592 | Feb 2019 | WO |
| WO2019062366 | Apr 2019 | WO |
| WO2019081777 | May 2019 | WO |
| WO2019086958 | May 2019 | WO |
| WO2019102484 | May 2019 | WO |
| WO2019116369 | Jun 2019 | WO |
| WO2019118371 | Jun 2019 | WO |
| WO2019135011 | Jul 2019 | WO |
| WO2019135028 | Jul 2019 | WO |
| WO-2019144036 | Jul 2019 | WO |
| WO2019147504 | Aug 2019 | WO |
| WO2019147846 | Aug 2019 | WO |
| WO2019154124 | Aug 2019 | WO |
| WO2019164516 | Aug 2019 | WO |
| WO2019195860 | Oct 2019 | WO |
| WO2019209927 | Oct 2019 | WO |
| WO2019222694 | Nov 2019 | WO |
| WO2019241777 | Dec 2019 | WO |
| WO2020051147 | Mar 2020 | WO |
| WO2020051591 | Mar 2020 | WO |
| WO2020072199 | Apr 2020 | WO |
| WO2020072201 | Apr 2020 | WO |
| WO2020073050 | Apr 2020 | WO |
| WO2020123719 | Jun 2020 | WO |
| WO2020157018 | Aug 2020 | WO |
| WO2020163112 | Aug 2020 | WO |
| WO2020180485 | Sep 2020 | WO |
| WO2020236830 | Nov 2020 | WO |
| WO2020247907 | Dec 2020 | WO |
| WO2021021482 | Feb 2021 | WO |
| WO2021028867 | Feb 2021 | WO |
| WO2021034497 | Feb 2021 | WO |
| WO2021086850 | May 2021 | WO |
| WO2021087400 | May 2021 | WO |
| WO2021091754 | May 2021 | WO |
| WO2021113143 | Jun 2021 | WO |
| WO2021178560 | Sep 2021 | WO |
| WO2021183610 | Sep 2021 | WO |
| WO2021207545 | Oct 2021 | WO |
| WO2021257278 | Dec 2021 | WO |
| WO2021257722 | Dec 2021 | WO |
| WO2022010974 | Jan 2022 | WO |
| WO2022046678 | Mar 2022 | WO |
| WO2022047095 | Mar 2022 | WO |
| WO2022047160 | Mar 2022 | WO |
| WO2022047274 | Mar 2022 | WO |
| WO2022047393 | Mar 2022 | WO |
| WO2022047395 | Mar 2022 | WO |
| WO2022066713 | Mar 2022 | WO |
| WO2022066720 | Mar 2022 | WO |
| WO2022121057 | Jun 2022 | WO |
| WO2022174160 | Aug 2022 | WO |
| WO202271851 | Dec 2022 | WO |
| WO2023034936 | Mar 2023 | WO |
| WO2023049625 | Mar 2023 | WO |
| WO2023064910 | Apr 2023 | WO |
| WO2022204138 | Sep 2024 | WO |
| Entry |
|---|
| Christian Schaefer, Large heart valves—small heart valves, Oct. 19, 2015, ISMAAP (Year: 2015). |
| Westaby et al.; Adult human valve dimensions and their surgical significance; The American Journal of Cardiology; 53(4); pp. 552-556; Feb. 1984. |
| Argento et al.; U.S. Appl. No. 18/185,330 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Mar. 16, 2023. |
| Adamek-Bowers et al.; U.S. Appl. No. 18/255,763 entitled “Mitral valve implants,” filed Jun. 2, 2023. |
| Argento et al.; U.S. Appl. No. 18/002,219 entitled “Minimal frame prosthetic cardiac valve delivery devices, systems, and methods,” filed Dec. 16, 2022. |
| Adamek-Bowers et al.; U.S. Appl. No. 18/043,458 entitled “Prosthetic valve delivery system,” filed Feb. 28, 2023. |
| Backus et al.; U.S. Appl. No. 18/004,609 entitled “Valve delivery system,” filed Jan. 6, 2023. |
| Mulcahy et al.; U.S. Appl. No. 18/043,480 entitled “Prosthetic cardiac valve delivery devices, systems, and methods,” filed Feb. 28, 2023. |
| Adamek-Bowers et al.; U.S. Appl. No. 18/043,499 entitled “Interface for prosthetic cardiac valve and delivery systems,” filed Feb. 28, 2023. |
| Salahieh et al.; U.S. Appl. No. 18/043,519 entitled “Flared prosthetic cardiac valve delivery devices and systems,” filed Feb. 28, 2023. |
| Scott et al.; U.S. Appl. No. 18/043,526 entitled “Access sheath for prosthetic cardiac valve delivery systems,” filed Feb. 28, 2023. |
| Yang et al.; U.S. Appl. No. 18/043,542 entitled “Anchor for prosthetic cardiac valve devices,” filed Feb. 28, 2023. |
| Argento et al.; U.S. Appl. No. 18/246,307 entitled “Systems, methods, and devices for expandable sensors,” filed Mar. 22, 2023. |
| Argento et al.; U.S. Appl. No. 18/246,311 entitled “Prosthetic cardiac valve sensor devices, systems, and methods with imaging,” filed Mar. 22, 2023. |
| Argento et al.; U.S. Appl. No. 18/494,520 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Oct. 25, 2023. |
| Mulcahy et al.; U.S. Appl. No. 18/573,816 entitled “Prosthetic cardiac valve delivery devices, systems, and methods,” filed Dec. 22, 2023. |
| Boyd et al., U.S. Appl. No. 18/688,735 entitled “Guide catheter for prosthetic cardiac valve delivery systems,” filed Mar. 1, 2024. |
| Masterclass; Knit vs. Woven: Learn How to Identify the Two Fabric Types; Jun. 7, 2021; 13 pages; retrieved from the internet (https://www.masterclass.com/articles/knit-vs-woven-learn-how-to-identify-the-two-fabric-types) on Nov. 15, 2024. |
| Yang et al.; U.S. Appl. No. 18/700,621 entitled “Cardiac valve prosthesis delivery system and methods of use,” filed Apr. 11, 2024. |
| Argento et al.; U.S. Appl. No. 18/639,743 entitled “Prosthetic cardiac valve devices, systems and methods,” filed Apr. 18, 2024. |
| Number | Date | Country | |
|---|---|---|---|
| 20220175522 A1 | Jun 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63274821 | Nov 2021 | US | |
| 63173281 | Apr 2021 | US | |
| 63121812 | Dec 2020 | US |